US20040235907A1 - Treatment of diabetes and related pathologies - Google Patents
Treatment of diabetes and related pathologies Download PDFInfo
- Publication number
- US20040235907A1 US20040235907A1 US10/881,864 US88186404A US2004235907A1 US 20040235907 A1 US20040235907 A1 US 20040235907A1 US 88186404 A US88186404 A US 88186404A US 2004235907 A1 US2004235907 A1 US 2004235907A1
- Authority
- US
- United States
- Prior art keywords
- compound
- insulin
- pyridoxal
- effective amount
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C(=O)OC1=C(C=O)C(CO)=CN=C1C Chemical compound [1*]C(=O)OC1=C(C=O)C(CO)=CN=C1C 0.000 description 7
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- This invention relates to methods of treating insulin-dependent diabetes mellitus, noninsulin-dependent diabetes mellitus, and related conditions and symptoms.
- Diabetes mellitus is a condition in which blood glucose levels are abnormally high because the body is unable to produce enough insulin to maintain normal blood glucose levels or is unable to adequately respond to the insulin produced.
- Insulin-dependent diabetes mellitus arises when the body produces little or no insulin. About 10% of all diabetics have type I diabetes.
- Noninsulin-dependent diabetes mellitus arises when the body cannot adequately respond to the insulin that is produced in response to blood glucose levels.
- Type II diabetes is often associated with hyperglycemia (high plasma glucose levels due to decreased glucose utilization) and hyperinsulinemia (high plasma insulin levels due to decreased insulin receptors available), factors that contribute to insulin resistance.
- Drug therapy for type I diabetes mellitus requires the administration of insulin; however, drug therapy for type II diabetes mellitus usually involves the administration of insulin and/or oral hypoglycemic drugs to lower blood glucose levels. If the oral hypoglycemic drugs fail to control blood sugar, then insulin, either alone or in combination with the hypoglycemic drugs, will usually be administered.
- diabetes mellitus Although many of the symptoms of diabetes mellitus may be controlled by insulin therapy, the long-term complications of both type I and type II diabetes mellitus are severe and may reduce life expectancy by as much as one third. Over time, elevated blood glucose levels damage blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, and white blood cell function.
- insulin therapy may result in insulin allergy, insulin resistance, atrophy of the subcutaneous fat at the site of insulin injection (i.e., lipoatrophy), enlargement of subcutaneous fat deposit (i.e., lipohypertrophy) due to lipogenic action of high local concentration of insulin, and insulin adema.
- the present invention provides methods for treating insulin-dependent diabetes mellitus, noninsulin-dependent diabetes mellitus, and related conditions and symptoms.
- One embodiment includes a method of treating diabetes mellitus in a mammal by administering a therapeutically effective amount of a compound, such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.
- a compound such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.
- the invention provides a method of treating diabetes mellitus in a mammal by concurrently administering a therapeutically effective amount of a combination of insulin and a compound, such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.
- a compound such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.
- the invention provides a method of treating noninsulin-dependent diabetes mellitus in a mammal by concurrently administering a therapeutically effective amount of a combination of a hypoglycemic compound and a compound, such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.
- a hypoglycemic compound such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.
- FIG. 1 shows the effect of P-5-P and insulin alone or in combination on plasma glucose levels in rats induced with Type I diabetes.
- FIG. 2 shows the effect of P-5-P and insulin alone or in combination on plasma insulin levels in rats induced with Type I diabetes.
- FIG. 3 shows the effect of P-5-P and tolbutamide alone or in combination on plasma glucose levels in rats induced with Type II diabetes.
- FIG. 4 shows the effect of P-5-P and tolbutamide alone or in combination on plasma insulin levels in rats induced with Type II diabetes.
- FIG. 5 shows the effect of P-5-P and tolbutamide alone or in combination on increased systolic blood pressure in rats induced with Type II diabetes.
- the present invention provides methods for treatment of diabetes mellitus and related conditions and symptoms.
- diabetes mellitus and related conditions include insulin-dependent diabetes mellitus (type I diabetes), noninsulin-dependent diabetes mellitus (type II diabetes), insulin resistance, hyperinsulinemia, and diabetes-induced hypertension.
- Other diabetes-related conditions include obesity and damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, and immune system.
- treatment include preventing inhibiting, and alleviating diabetes mellitus and related conditions and symptoms.
- the treatment may be carried out by administering a therapeutically effective amount of a compound suitable for use in methods of the invention.
- the treatment may be carried out by concurrently administering a therapeutically effective amount of a combination of insulin and a compound suitable for use in methods of the invention.
- the treatment may involve concurrently administering a therapeutically effective amount of a combination of a hypoglycemic compound and a compound suitable for use in methods of the invention when the diabetes mellitus and related conditions to be treated is type II diabetes, insulin resistance, hyperinsulinemia, diabetes-induced hypertension, obesity, or damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system.
- a “therapeutically effective amount” as used herein includes a prophylactic amount, for example, an amount effective for preventing or protecting against diabetes mellitus and related conditions and symptoms, and amounts effective for alleviating or healing diabetes mellitus and related conditions and symptoms.
- a prophylactic amount for example, an amount effective for preventing or protecting against diabetes mellitus and related conditions and symptoms, and amounts effective for alleviating or healing diabetes mellitus and related conditions and symptoms.
- the insulin and/or hypoglycemic compound may be administered in a dosage amount that is less than the dosage amount required when the insulin and/or hypoglycemic compound is the sole active ingredient.
- the side effects associated therewith should accordingly be reduced and/or the onset of the long-term complications that arise from diabetes mellitus and related conditions may be delayed.
- Compounds suitable for use in the methods of the invention include pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, 3-acylated pyridoxal analogues, pharmaceutically acceptable acid addition salts thereof, or a mixture thereof.
- 3-Acylated pyridoxal analogues include prodrugs of pyridoxal that provide for slower metabolism to pyridoxal in vivo.
- one suitable 3-acylated analogue of pyridoxal (2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine) is a compound of the formula I:
- R 1 is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group.
- alkyl group includes a straight or branched saturated aliphatic hydrocarbon chain having from 1 to 8 carbon atoms, such as, for example, methyl, ethyl, propyl, isopropyl (1-methylethyl), butyl, tert-butyl (1,1-dimethylethyl), and the like.
- alkenyl group includes an unsaturated aliphatic hydrocarbon chain having from 2 to 8 carbon atoms, such as, for example, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-methyl-1-propenyl, and the like.
- the above alkyl or alkenyl groups may optionally be interrupted in the chain by a heteroatom, such as, for example, a nitrogen or oxygen atom, forming an alkylaminoalkyl or alkoxyalkyl group, for example, methylaminoethyl or methoxymethyl, and the like.
- a heteroatom such as, for example, a nitrogen or oxygen atom, forming an alkylaminoalkyl or alkoxyalkyl group, for example, methylaminoethyl or methoxymethyl, and the like.
- alkoxy group includes an alkyl group as defined above joined to an oxygen atom having preferably from 1 to 4 carbon atoms in a straight or branched chain, such as, for example, methoxy, ethoxy, propoxy, isopropoxy (1-methylethoxy), butoxy, tert-butoxy (1,1-dimethylethoxy), and the like.
- dialkylamino group includes two alkyl groups as defined above joined to a nitrogen atom, in which the alkyl group has preferably 1 to 4 carbon atoms, such as, for example, dimethylamino, diethylamino, methylethylamino, methylpropylamino, diethylamino, and the like.
- aryl group includes an aromatic hydrocarbon group, including fused aromatic rings, such as, for example, phenyl and naphthyl. Such groups may be unsubstituted or substituted on the aromatic ring by, for example, an alkyl group of 1 to 4 carbon atoms, an alkoxy group of 1 to 4 carbon atoms, an amino group, a hydroxy group, or an acetyloxy group.
- R 1 groups for compounds of formula I are toluyl or naphthyl. Such R 1 groups when joined with a carbonyl group form an acyl group
- 3-acylated analogues of pyridoxal include, but are not limited to, 2-methyl-3-toluoyloxy-4-formyl-5-hydroxymethylpyridine and 2-methyl- ⁇ -naphthoyloxy-4-formyl-5-hydroxymethylpyridine.
- Another suitable analogue is a 3-acylated analogue of pyridoxal-4,5-aminal (1-secondary amino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) of the formula II:
- R 1 is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and
- R 2 is a secondary amino group.
- alkyl alkenyl
- alkoxy alkoxy
- dialkylamino alkyl
- aryl aryl
- secondary amino includes a group of the formula III:
- R 3 R 4 NH derived from a secondary amine R 3 R 4 NH, in which R 3 and R 4 are each independently alkyl, alkenyl, cycloalkyl, aryl, or, when R 3 and R 4 are taken together, may form a ring with the nitrogen atom and which may optionally be interrupted by a heteroatom, such as, for example, a nitrogen or oxygen atom.
- the terms “alkyl,” “alkenyl,” and “aryl” are used as defined above in forming secondary amino groups such as, for example, dimethylamino, methylethylamino, diethylamino, dialkylamino, phenylmethylamino, diphenylamino, and the like.
- cycloalkyl refers to a saturated hydrocarbon having from 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms, such as, for example, cyclopropyl, cyclopentyl, cyclohexyl, and the like.
- R 3 and R 4 When taken together with the nitrogen atom, they may form a cyclic secondary amino group, such as, for example, piperidino, and, when interrupted with a heteroatom, includes, for example, piperazino and morpholino.
- R 1 groups for compounds of formula II include toluyl, e.g., p-toluyl, naphthyl, tert-butyl, dimethylamino, acetylphenyl, hydroxyphenyl, or alkoxy, e.g., methoxy.
- 3-acylated analogues of pyridoxal-4,5-aminal include, but are not limited to, 1-morpholino-1,3-dihydro-7-(p-toluoyloxy)-6-methylfuro(3,4-c)pyridine; 1-morpholino-1,3-dihydro-7-( ⁇ -naphthoyloxy)-6-methylfuro(3,4-c)pyridine; 1-morpholino-1,3-dihydro-7-pivaloyloxy-6-methylfuro(3,4-c)pyridine; 1-morpholino-1,3-dihydro-7-carbamoyloxy-6-methylfuro(3,4-c)pyridine; and 1-morpholino-1,3-dihydro-7-acetylsalicyloxy-6-methylfuro(3,4-c)pyridine.
- the compounds of formula I may be prepared by reacting pyridoxal hydrochloride with an acyl halide in an aprotic solvent.
- a suitable acyl group is
- R 1 is as defined above.
- a particularly suitable acyl halide includes p-toluoyl chloride or ⁇ -naphthoyl chloride.
- a suitable aprotic solvent includes acetone, methylethylketone, and the like.
- the compounds of formula II may be prepared by reacting 1-secondary amino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine with an acyl halide in an aprotic solvent.
- An acyl group is
- a particularly suitable acyl halide includes p-toluoyl chloride, ⁇ -naphthoyl chloride, trimethylacetyl chloride, dimethylcarbamoyl chloride, and acetylsalicyloyl chloride.
- a particularly suitable secondary amino group includes morpholino.
- the compound 1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine may be prepared by methods known in the art, for example, by reacting morpholine and pyridoxal hydrochloride at a temperature of about 100° C. in a solvent.
- a suitable solvent includes, for example, toluene.
- other secondary amines as defined for R 2 may be used as reactants to prepare the appropriate 1-secondary amino compounds.
- the compounds of formula I may alternatively be prepared from the compounds of formula II by reacting a compound of formula II with an aqueous acid, such as, for example, aqueous acetic acid.
- an aqueous acid such as, for example, aqueous acetic acid.
- Pharmaceutically acceptable acid addition salts of the compounds suitable for use in methods of the invention include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc.
- nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like
- nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedio
- Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like.
- salts of amino acids such as arginate and the like and gluconate, galacturonate, n-methyl glutamine, etc. (see, e.g., Berge et al., J. Pharmaceutical Science, 66: 1-19 (1977).
- the acid addition salts of the basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.
- the free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner.
- the free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.
- the compounds suitable for use in methods of the invention are formulated into pharmaceutically acceptable unit dosage forms by conventional methods known to the pharmaceutical art.
- An effective but nontoxic quantity of the compound is employed in treatment.
- the compounds can be administered in enteral unit dosage forms, such as, for example, tablets, sustained release tablets, enteric coated tablets, capsules, sustained release capsules, enteric coated capsules, pills, powders, granules, solutions, and the like. They may also be administered parenterally, such as, for example, subcutaneously, intramuscularly, intradermally, intramammarally, intravenously, and other administrative methods known in the art.
- a pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound.
- a pharmaceutically acceptable carrier includes, but is not limited to, physiological saline, ringers, phosphate buffered saline, and other carriers known in the art.
- compositions may also include additives, for example, stabilizers, antioxidants, colorants, excipients, binders, thickeners, dispersing agents, readsorpotion enhancers, buffers, surfactants, preservatives, emulsifiers, isotonizing agents, and diluents.
- additives for example, stabilizers, antioxidants, colorants, excipients, binders, thickeners, dispersing agents, readsorpotion enhancers, buffers, surfactants, preservatives, emulsifiers, isotonizing agents, and diluents.
- Pharmaceutically acceptable carriers and additives are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not canceled or inhibited to such an extent that treatment is ineffective.
- compositions containing a pharmaceutically acceptable carrier and a compound suitable for use in methods of the invention are known to those of skill in the art. All methods may include the step of bringing the compound in association with the carrier and additives. In general, the formulations are prepared by uniformly and intimately bringing the compound of the invention into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired unit dosage form.
- the ordinarily skilled physician or veterinarian will readily determine and prescribe the therapeutically effective amount of the compound to treat the disease for which treatment is administered. In so proceeding, the physician or veterinarian could employ relatively low dosages at first, subsequently increasing the dose until a maximum response is obtained.
- the particular disease, the severity of the disease, the compound to be administered, the route of administration, and the characteristics of the mammal to be treated, for example, age, sex, and weight are considered in determining the effective amount to administer.
- a therapeutically effective amount of a compound to treat diabetes mellitus and related conditions and symptoms is in a range of about 0.1-100 mg/kg of a patient's body weight, more preferably in the range of about 0.5-50 mg/kg of a patient's body weight, per daily dose.
- the compound may be administered for periods of short and long duration.
- a therapeutically effective amount of a compound for treating diabetes mellitus and related conditions and symptoms can be administered prior to, concurrently with, or after the onset of the disease or symptom.
- the compound can be administered to treat diabetes mellitus type I, diabetes mellitus type II, or obesity.
- the compound can be administered to treat damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system.
- the compound can be administered to treat insulin resistance or hyperinsulinemia.
- the compound can be administered to treat diabetes-induced hypertension.
- the compound may be administered concurrently with insulin and/or a hypoglycemic compound to treat diabetes mellitus and related conditions and symptoms.
- the compound can be administered concurrently with insulin and/or a hypoglycemic compound to treat type I diabetes, type II diabetes, or obesity.
- the compound can be administered concurrently with insulin and/or hypoglycemic compound to treat damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system.
- the compound can be administered concurrently with insulin and/or hypoglycemic compound to treat insulin resistance or hyperinsulinemia.
- the compound can be administered concurrently with insulin and/or hypoglycemic compound to treat diabetes-induced hypertension.
- a compound may be administered concurrently with insulin to treat type I diabetes, type II diabetes, and related conditions and symptoms.
- type II diabetes insulin resistance, hyperinsulinemia, diabetes-induced hypertension, obesity, or damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system
- a compound may be administered concurrently with a hypoglycemic compound instead of insulin.
- a compound may be administered concurrently with insulin and a hypoglycemic compound to treat type II diabetes, insulin resistance, hyperinsulinemia, diabetes-induced hypertension, obesity, or damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system.
- Conscurrent administration includes administering a compound suitable for use in methods of the invention and insulin and/or a hypoglycemic compound in admixture, such as, for example, in a pharmaceutical composition, or as separate compounds, such as, for example, separate pharmaceutical compositions administered consecutively, simultaneously, or at different times.
- a compound suitable for use in methods of the invention and insulin and/or a hypoglycemic compound in admixture, such as, for example, in a pharmaceutical composition, or as separate compounds, such as, for example, separate pharmaceutical compositions administered consecutively, simultaneously, or at different times.
- the compound and insulin and/or hypoglycemic compound are administered separately, they are not administered so distant in time from each other that the compound and the insulin and/or hypoglycemic compound cannot interact and a lower dosage amount of insulin and/or hypoglycemic compound cannot be administered.
- Suitable hypoglycemic compounds include, for example, metformin, acarbose, acetohexamide, glimepiride, tolazamide, glipizide, glyburide, tolbutamide, chlorpropamide, thiazolidinediones, alpha glucosidase inhibitors, biguanindine derivatives, and troglitazone, and a mixture thereof.
- the hypoglycemic compound is tolbutamide.
- a physician or veterinarian of ordinary skill readily determines a subject who is exhibiting symptoms of diabetes mellitus and related conditions and symptoms. Regardless of the route of administration selected, the compound and the insulin and/or hypoglycemic compound are formulated into pharmaceutically acceptable unit dosage forms by conventional methods known to the pharmaceutical art. An effective but nontoxic quantity of the compound and the insulin and/or hypoglycemic compound is employed in the treatment of diabetes mellitus and related conditions and symptoms.
- the compound and the insulin may be concurrently administered parenterally in admixture or may be concurrently administered enterally and/or parenterally separately.
- the compound and the hypoglycemic compound may be concurrently administered enterally in admixture or may be administered enterally and/or parenterally separately.
- the compound may be concurrently administered with insulin and a hypoglycemic compound. Such administration would involve enteral and/or parenteral administration as described above.
- Parenteral administration includes subcutaneous, intramuscular, intradermal, intramammary, intravenous, and other administrative methods known in the art.
- Enteral administration includes tablets, sustained release tablets, enteric coated tablets, capsules, sustained release capsules, enteric coated capsules, pills, powders, granules, solutions, and the like.
- a pharmaceutical composition suitable for administration includes a pharmaceutically acceptable carrier and a compound suitable for use in methods of the invention and, optionally, insulin and/or a hypoglycemic compound.
- a pharmaceutically acceptable carrier includes, but is not limited to, physiological saline, ringers, phosphate buffered saline, and other carriers known in the art.
- Pharmaceutical compositions may also include stabilizers, antioxidants, colorants, and diluents.
- Pharmaceutically acceptable carriers and additives are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not canceled or inhibited to such an extent that treatment is ineffective.
- compositions containing a pharmaceutically acceptable carrier and a compound suitable for use in methods of the invention and, optionally, insulin and/or a hypoglycemic compound are known to those of skill in the art. All methods may include the step of bringing the compound and, optionally, a hypoglycemic compound in association with the carrier or additives. In general, the formulations are prepared by uniformly and intimately bringing the compound into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired unit dosage form.
- the compound When concurrently administering a compound with insulin and/or a hypoglycemic compound, the compound is administered in a range of about 0.1-100 mg per daily dose, typically 0.5-50 mg/kg of body weight per daily dose.
- a hypoglycemic compound is administered in a range of about 1 to 300 mg per daily dose, typically 1 to 200 mg per daily dose.
- Insulin is typically administered in a range of about 0.1 to 2 units/kg of a patient's body weight per daily dose.
- a “unit” of insulin refers to that amount of insulin necessary to lower the blood-sugar level in a rabbit by 50% in 1 to 3 hours.
- a mixture of morpholine (20 g) and toluene (100 mL) was stirred and heated using an oil bath set to 100° C. for 15 minutes. Pyridoxal hydrochloride (10 g) was then added and the reaction mixture was stirred at 100° C. for two hours.
- the reaction mixture was then concentrated by distillation of the toluene and morpholine.
- the concentrated reaction mixture was washed three times by adding toluene (100 mL) and removing the toluene by distillation. After washing, the residue was dissolved in toluene and filtered, and then hexane was added until precipitation began, at which time the reaction mixture was left overnight at room temperature. Crystals were collected and washed thoroughly with hexane.
- Nuclear magnetic resonance spectroscopy (NMR) and mass spectroscopy confirmed the identity of the synthesized compound.
- the purity of the compound was analyzed by high performance liquid chromatography (HPLC) using a C-18 reverse phase column and water/acetonitrile as solvent (1-100% acetonitrile over 25 minutes).
- the 3-toluate of pyridoxal is synthesized by reacting the compound of Example 2 with 80% aqueous acetic acid at 60° C. for 30 minutes, and then diluting with water and extracting by ethyl acetate. The ethyl acetate layer is washed with 5% aqueous sodium bicarbonate, dried with magnesium sulfate, and evaporated to dryness. The compound is also analyzed as described supra.
- the 3- ⁇ -naphthoate of pyridoxal is prepared by reacting the compound of Example 4 with 80% aqueous acetic acid at 60° C. for 30 minutes, followed by diluting with water and extracting by ethyl acetate. The ethyl acetate layer is then washed with 5% aqueous sodium bicarbonate, dried with magnesium sulfate, and evaporated to dryness. The compound is also analyzed as described supra.
- rats are administered pyridoxal-5′-phosphate, either alone or in combination with insulin, after being experimentally induced with type I diabetes, and their urine and blood glucose and insulin levels are determined.
- mice Male Sprague-Dawley (Charles River Laboratories, Montreal, Canada) rats weighing approximately 200 g are randomly separated into control and experimental groups. All experimental animals are given an intravenous injection of 0.1 M citrate buffered streptozotocin (pH 4.5) at a dosage of 65 mg/kg of body weight to induce diabetes mellitus. All control animals receive an intravenous injection of 0.1 M citrate buffer (pH 4.5) alone.
- 0.1 M citrate buffered streptozotocin pH 4.5
- One experimental group of rats also receives daily doses of pyridoxal-5′-phosphate (25 mg/kg body weight) (Aldrich Canada Ltd., Ontario, Canada).
- a second experimental group receives daily subcutanteous injections of Humulin® N (3 units per day) (insulin isophene, human biosynthetic; Eli Lilly and Co., Indianapolis, Ind.).
- a third experimental group receives both daily subcutaneous injections of Humulin® N (3 units per day) and a daily dose of pyridoxal-5′-phosphate (25 mg/kg body weight).
- a fourth experimental group receives daily subcutaneous injections of Humulin® N (1.5 units per day).
- a fifth experimental group receives both daily subcutaneous injections of Humulin® N (1.5 units per day) and a daily dose of pyridoxal-5′-phosphate (25 mg/kg body weight).
- the experimental group of rats that receive daily doses of pyridoxal-5′-phosphate and daily injections of Humulin® N show reduced levels of glucose and insulin in blood and urine samples when compared with the group of rats that receive daily injections of Humulin® N without receiving daily doses of pyridoxal-5′-phosphate.
- FIG. 1 demonstrates the effect of P-5-P and insulin alone or in combination on increased plasma glucose levels in a Type I diabetes indication of hyperglycemia. It can be seen in FIG. 1 that Insulin (1 unit and 3 unit) and P-5-P significantly reduced the plasma glucose levels when compared to diabetic group. Moreover a decreased dose of insulin was needed in the presence of P-5-P to produce the same effect as with a full dose of 3 units of insulin.
- FIG. 2 demonstrates the effect of P-5-P and insulin alone or in combination on plasma glucose levels in a Type I diabetes indication of hyperglycemia. It can be seen in FIG. 2 that Insulin (1 unit and 3 unit) and P-5-P significantly increased the plasma insulin levels when compared to diabetic group. Moreover a decreased dose of insulin was needed in the presence of P-5-P to produce the same effect as with a full dose of 3 units of insulin.
- Acarbose reduces blood pressure in sucrose induced hypertension in rats .
- Madar Z et al: Isr J Med Sci; 33:153-159 a high sucrose or fructose diet for a prolonged period is one technique used to induce Type II diabetes, specifically hypertension associated with hyperglycemia and hyperinsulinemia in animals.
- sucrose group that was fed 35% sucrose (35 gm sucrose/100 ml of drinking water/day) with an average intake of 150 ml/rat/day
- sucrose+tolbutamide group that was fed sucrose as stated in b above and administered 40 mg/kg orally/day of tolbutamide
- sucrose+P-5-P+tolbutamide group that was fed sucrose as stated in b above, 25 mg/kg orally/day of P-5-P, and administered 40 mg/kg orally/day of tolbutamide
- sucrose+P-5-P+tolbutamide group that was fed sucrose as stated in b above, 25 mg/kg orally/day of P-5-P, and administered 20 mg/kg, orally/day of tolbutamide
- FIG. 3 demonstrates the effect of P-5-P and tolbutamide alone or in combination on increased plasma glucose levels in a Type II diabetes indication of hyperglycemia. It can be seen in FIG. 3 that tolbutamide (40 and 20 mg/kg) and P-5-P significantly decreased the plasma glucose levels when compared to diabetic group. Moreover a decreased dose of tolbutamide was needed in the presence of P-5-P to produce the same effect as with a full dose of 40 mg/kg tolbutamide.
- FIG. 4 demonstrates the effect of P-5-P and tolbutamide alone or in combination on increased plasma insulin levels in a Type II diabetes indication of hyperglycemia. It can be seen in FIG. 4 that tolbutamide (40 and 20 mg/kg) and P-5-P significantly decreased the plasma insulin levels when compared to diabetic group. Moreover a decreased dose of tolbutamide was needed in the presence of P-5-P to produce the same or better effect as with a full dose of 40 mg/kg tolbutamide.
- FIG. 5 demonstrates the effect of P-5-P and tolbutamide alone or in combination on increased systolic blood pressure in a Type II diabetes indication of hyperglycemia. It can be seen in FIG. 5 that that P-5-P significantly decreased the rise in systolic blood pressure when compared to diabetic and tolbutamide treatment groups. Moreover when the rats were treated with P-5-P and tolbutamide (40 mg/kg), the decrease in systolic blood pressure was significantly greater when compared to rats treated with P-5-P or tolbutamide alone.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application claims priority to provisional application Serial No. 60/143,466, filed on Jul. 13, 1999.
- This invention relates to methods of treating insulin-dependent diabetes mellitus, noninsulin-dependent diabetes mellitus, and related conditions and symptoms.
- Diabetes mellitus is a condition in which blood glucose levels are abnormally high because the body is unable to produce enough insulin to maintain normal blood glucose levels or is unable to adequately respond to the insulin produced. Insulin-dependent diabetes mellitus (often referred to as type I diabetes) arises when the body produces little or no insulin. About 10% of all diabetics have type I diabetes. Noninsulin-dependent diabetes mellitus (often referred to as type II diabetes) arises when the body cannot adequately respond to the insulin that is produced in response to blood glucose levels. Type II diabetes is often associated with hyperglycemia (high plasma glucose levels due to decreased glucose utilization) and hyperinsulinemia (high plasma insulin levels due to decreased insulin receptors available), factors that contribute to insulin resistance.
- Available treatments include weight control, exercise, diet, and drug therapy. Drug therapy for type I diabetes mellitus requires the administration of insulin; however, drug therapy for type II diabetes mellitus usually involves the administration of insulin and/or oral hypoglycemic drugs to lower blood glucose levels. If the oral hypoglycemic drugs fail to control blood sugar, then insulin, either alone or in combination with the hypoglycemic drugs, will usually be administered.
- Although many of the symptoms of diabetes mellitus may be controlled by insulin therapy, the long-term complications of both type I and type II diabetes mellitus are severe and may reduce life expectancy by as much as one third. Over time, elevated blood glucose levels damage blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, and white blood cell function.
- Moreover, insulin therapy may result in insulin allergy, insulin resistance, atrophy of the subcutaneous fat at the site of insulin injection (i.e., lipoatrophy), enlargement of subcutaneous fat deposit (i.e., lipohypertrophy) due to lipogenic action of high local concentration of insulin, and insulin adema.
- Thus, it would be desirable to find an alternative to the above-described therapies or to administer a drug therapy that may reduce the amount of insulin or hypoglycemic drug required, yet maintain the effectiveness of the insulin or hypoglycemic drug administered.
- The present invention provides methods for treating insulin-dependent diabetes mellitus, noninsulin-dependent diabetes mellitus, and related conditions and symptoms. One embodiment includes a method of treating diabetes mellitus in a mammal by administering a therapeutically effective amount of a compound, such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.
- In another embodiment, the invention provides a method of treating diabetes mellitus in a mammal by concurrently administering a therapeutically effective amount of a combination of insulin and a compound, such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.
- In still another embodiment, the invention provides a method of treating noninsulin-dependent diabetes mellitus in a mammal by concurrently administering a therapeutically effective amount of a combination of a hypoglycemic compound and a compound, such as pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof.
- FIG. 1 shows the effect of P-5-P and insulin alone or in combination on plasma glucose levels in rats induced with Type I diabetes.
- FIG. 2 shows the effect of P-5-P and insulin alone or in combination on plasma insulin levels in rats induced with Type I diabetes.
- FIG. 3 shows the effect of P-5-P and tolbutamide alone or in combination on plasma glucose levels in rats induced with Type II diabetes.
- FIG. 4 shows the effect of P-5-P and tolbutamide alone or in combination on plasma insulin levels in rats induced with Type II diabetes.
- FIG. 5 shows the effect of P-5-P and tolbutamide alone or in combination on increased systolic blood pressure in rats induced with Type II diabetes.
- The present invention provides methods for treatment of diabetes mellitus and related conditions and symptoms. Such diabetes mellitus and related conditions include insulin-dependent diabetes mellitus (type I diabetes), noninsulin-dependent diabetes mellitus (type II diabetes), insulin resistance, hyperinsulinemia, and diabetes-induced hypertension. Other diabetes-related conditions include obesity and damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, and immune system.
- In accordance with the present invention, it has been found that compounds, such as, for example, pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, a 3-acylated pyridoxal analogue, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof, either alone or in combination with insulin and/or hypoglycemic compounds can be used in the treatment of the above-identified diseases and conditions. As used herein, “treatment” and “treating” include preventing inhibiting, and alleviating diabetes mellitus and related conditions and symptoms. In some instances, the treatment may be carried out by administering a therapeutically effective amount of a compound suitable for use in methods of the invention. In other instances, the treatment may be carried out by concurrently administering a therapeutically effective amount of a combination of insulin and a compound suitable for use in methods of the invention. In still other instances, the treatment may involve concurrently administering a therapeutically effective amount of a combination of a hypoglycemic compound and a compound suitable for use in methods of the invention when the diabetes mellitus and related conditions to be treated is type II diabetes, insulin resistance, hyperinsulinemia, diabetes-induced hypertension, obesity, or damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system.
- A “therapeutically effective amount” as used herein includes a prophylactic amount, for example, an amount effective for preventing or protecting against diabetes mellitus and related conditions and symptoms, and amounts effective for alleviating or healing diabetes mellitus and related conditions and symptoms. Generally, by administering a compound suitable for use in methods of the invention concurrently with insulin and/or a hypoglycemic compound the insulin and/or hypoglycemic compound may be administered in a dosage amount that is less than the dosage amount required when the insulin and/or hypoglycemic compound is the sole active ingredient. By administering lower dosage amounts of insulin and/or a hypoglycemic compound, the side effects associated therewith should accordingly be reduced and/or the onset of the long-term complications that arise from diabetes mellitus and related conditions may be delayed.
- Compounds suitable for use in the methods of the invention include pyridoxal-5′-phosphate, pyridoxal, pyridoxamine, pyridoxine, 3-acylated pyridoxal analogues, pharmaceutically acceptable acid addition salts thereof, or a mixture thereof. 3-Acylated pyridoxal analogues include prodrugs of pyridoxal that provide for slower metabolism to pyridoxal in vivo. For example, one suitable 3-acylated analogue of pyridoxal (2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine) is a compound of the formula I:
- or a pharmaceutically acceptable acid addition salt thereof, wherein
- R1 is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group.
- The term “alkyl” group includes a straight or branched saturated aliphatic hydrocarbon chain having from 1 to 8 carbon atoms, such as, for example, methyl, ethyl, propyl, isopropyl (1-methylethyl), butyl, tert-butyl (1,1-dimethylethyl), and the like.
- The term “alkenyl” group includes an unsaturated aliphatic hydrocarbon chain having from 2 to 8 carbon atoms, such as, for example, ethenyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-methyl-1-propenyl, and the like.
- The above alkyl or alkenyl groups may optionally be interrupted in the chain by a heteroatom, such as, for example, a nitrogen or oxygen atom, forming an alkylaminoalkyl or alkoxyalkyl group, for example, methylaminoethyl or methoxymethyl, and the like.
- The term “alkoxy” group includes an alkyl group as defined above joined to an oxygen atom having preferably from 1 to 4 carbon atoms in a straight or branched chain, such as, for example, methoxy, ethoxy, propoxy, isopropoxy (1-methylethoxy), butoxy, tert-butoxy (1,1-dimethylethoxy), and the like.
- The term “dialkylamino” group includes two alkyl groups as defined above joined to a nitrogen atom, in which the alkyl group has preferably 1 to 4 carbon atoms, such as, for example, dimethylamino, diethylamino, methylethylamino, methylpropylamino, diethylamino, and the like.
- The term “aryl” group includes an aromatic hydrocarbon group, including fused aromatic rings, such as, for example, phenyl and naphthyl. Such groups may be unsubstituted or substituted on the aromatic ring by, for example, an alkyl group of 1 to 4 carbon atoms, an alkoxy group of 1 to 4 carbon atoms, an amino group, a hydroxy group, or an acetyloxy group.
-
- which preferred for compounds of formula I include toluoyl or β-naphthoyl. Of the toluoyl group, the p-isomer is more preferred.
- Examples of 3-acylated analogues of pyridoxal include, but are not limited to, 2-methyl-3-toluoyloxy-4-formyl-5-hydroxymethylpyridine and 2-methyl-β-naphthoyloxy-4-formyl-5-hydroxymethylpyridine.
-
- or a pharmaceutically acceptable acid addition salt thereof, wherein
- R1 is a straight or branched alkyl group, a straight or branched alkenyl group, in which an alkyl or alkenyl group may be interrupted by a nitrogen or oxygen atom; an alkoxy group; a dialkylamino group; or an unsubstituted or substituted aryl group; and
- R2 is a secondary amino group.
- The terms “alkyl,” “alkenyl,” “alkoxy,” “dialkylamino,” and “aryl” are as defined above.
-
- derived from a secondary amine R3R4NH, in which R3 and R4 are each independently alkyl, alkenyl, cycloalkyl, aryl, or, when R3 and R4 are taken together, may form a ring with the nitrogen atom and which may optionally be interrupted by a heteroatom, such as, for example, a nitrogen or oxygen atom. The terms “alkyl,” “alkenyl,” and “aryl” are used as defined above in forming secondary amino groups such as, for example, dimethylamino, methylethylamino, diethylamino, dialkylamino, phenylmethylamino, diphenylamino, and the like.
- The term “cycloalkyl” refers to a saturated hydrocarbon having from 3 to 8 carbon atoms, preferably 3 to 6 carbon atoms, such as, for example, cyclopropyl, cyclopentyl, cyclohexyl, and the like.
- When R3 and R4 are taken together with the nitrogen atom, they may form a cyclic secondary amino group, such as, for example, piperidino, and, when interrupted with a heteroatom, includes, for example, piperazino and morpholino.
-
- which preferred for compounds and formula II include toluoyl, β-naphthoyl, pivaloyl, dimethylcarbamoyl, acetylsalicyloyl, salicyloyl, or alkoxycarbonyl. A preferred secondary amino group may be morpholino.
- Examples of 3-acylated analogues of pyridoxal-4,5-aminal include, but are not limited to, 1-morpholino-1,3-dihydro-7-(p-toluoyloxy)-6-methylfuro(3,4-c)pyridine; 1-morpholino-1,3-dihydro-7-(β-naphthoyloxy)-6-methylfuro(3,4-c)pyridine; 1-morpholino-1,3-dihydro-7-pivaloyloxy-6-methylfuro(3,4-c)pyridine; 1-morpholino-1,3-dihydro-7-carbamoyloxy-6-methylfuro(3,4-c)pyridine; and 1-morpholino-1,3-dihydro-7-acetylsalicyloxy-6-methylfuro(3,4-c)pyridine.
-
- wherein R1 is as defined above. A particularly suitable acyl halide includes p-toluoyl chloride or β-naphthoyl chloride. A suitable aprotic solvent includes acetone, methylethylketone, and the like.
-
- wherein R1 is as defined above. A particularly suitable acyl halide includes p-toluoyl chloride, β-naphthoyl chloride, trimethylacetyl chloride, dimethylcarbamoyl chloride, and acetylsalicyloyl chloride. A particularly suitable secondary amino group includes morpholino.
- The compound 1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine may be prepared by methods known in the art, for example, by reacting morpholine and pyridoxal hydrochloride at a temperature of about 100° C. in a solvent. A suitable solvent includes, for example, toluene. Similarly, other secondary amines as defined for R2 may be used as reactants to prepare the appropriate 1-secondary amino compounds.
- The compounds of formula I may alternatively be prepared from the compounds of formula II by reacting a compound of formula II with an aqueous acid, such as, for example, aqueous acetic acid.
- One skilled in the art would recognize variations in the sequence and would recognize variations in the appropriate reaction conditions from the analogous reactions shown or otherwise known that may be appropriately used in the above-described processes to make the compounds of formulas I and II herein.
- The products of the reactions described herein are isolated by conventional means such as extraction, distillation, chromatography, and the like.
- Pharmaceutically acceptable acid addition salts of the compounds suitable for use in methods of the invention include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate, n-methyl glutamine, etc. (see, e.g., Berge et al.,J. Pharmaceutical Science, 66: 1-19 (1977).
- The acid addition salts of the basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner. The free base form may be regenerated by contacting the salt form with a base and isolating the free base in the conventional manner. The free base forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free base for purposes of the present invention.
- A physician or veterinarian of ordinary skill readily determines a subject who is exhibiting symptoms of any one or more of the diseases described above. Regardless of the route of administration selected, the compounds suitable for use in methods of the invention are formulated into pharmaceutically acceptable unit dosage forms by conventional methods known to the pharmaceutical art. An effective but nontoxic quantity of the compound is employed in treatment. The compounds can be administered in enteral unit dosage forms, such as, for example, tablets, sustained release tablets, enteric coated tablets, capsules, sustained release capsules, enteric coated capsules, pills, powders, granules, solutions, and the like. They may also be administered parenterally, such as, for example, subcutaneously, intramuscularly, intradermally, intramammarally, intravenously, and other administrative methods known in the art.
- Although it is possible for a compound suitable for use in methods of the invention to be administered alone in a unit dosage form, preferably the compound is administered in admixture as a pharmaceutical composition suitable for use in methods of the invention. A pharmaceutical composition comprises a pharmaceutically acceptable carrier and a compound. A pharmaceutically acceptable carrier includes, but is not limited to, physiological saline, ringers, phosphate buffered saline, and other carriers known in the art. Pharmaceutical compositions may also include additives, for example, stabilizers, antioxidants, colorants, excipients, binders, thickeners, dispersing agents, readsorpotion enhancers, buffers, surfactants, preservatives, emulsifiers, isotonizing agents, and diluents. Pharmaceutically acceptable carriers and additives are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not canceled or inhibited to such an extent that treatment is ineffective.
- Methods of preparing pharmaceutical compositions containing a pharmaceutically acceptable carrier and a compound suitable for use in methods of the invention are known to those of skill in the art. All methods may include the step of bringing the compound in association with the carrier and additives. In general, the formulations are prepared by uniformly and intimately bringing the compound of the invention into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired unit dosage form.
- The ordinarily skilled physician or veterinarian will readily determine and prescribe the therapeutically effective amount of the compound to treat the disease for which treatment is administered. In so proceeding, the physician or veterinarian could employ relatively low dosages at first, subsequently increasing the dose until a maximum response is obtained. Typically, the particular disease, the severity of the disease, the compound to be administered, the route of administration, and the characteristics of the mammal to be treated, for example, age, sex, and weight, are considered in determining the effective amount to administer. Generally, a therapeutically effective amount of a compound to treat diabetes mellitus and related conditions and symptoms is in a range of about 0.1-100 mg/kg of a patient's body weight, more preferably in the range of about 0.5-50 mg/kg of a patient's body weight, per daily dose. The compound may be administered for periods of short and long duration.
- A therapeutically effective amount of a compound for treating diabetes mellitus and related conditions and symptoms can be administered prior to, concurrently with, or after the onset of the disease or symptom. The compound can be administered to treat diabetes mellitus type I, diabetes mellitus type II, or obesity. Preferably, the compound can be administered to treat damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system. Still preferably, the compound can be administered to treat insulin resistance or hyperinsulinemia. Also preferably, the compound can be administered to treat diabetes-induced hypertension.
- Moreover, the compound may be administered concurrently with insulin and/or a hypoglycemic compound to treat diabetes mellitus and related conditions and symptoms. The compound can be administered concurrently with insulin and/or a hypoglycemic compound to treat type I diabetes, type II diabetes, or obesity. Preferably, the compound can be administered concurrently with insulin and/or hypoglycemic compound to treat damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system. Still preferably, the compound can be administered concurrently with insulin and/or hypoglycemic compound to treat insulin resistance or hyperinsulinemia. Also preferably, the compound can be administered concurrently with insulin and/or hypoglycemic compound to treat diabetes-induced hypertension.
- Typically, a compound may be administered concurrently with insulin to treat type I diabetes, type II diabetes, and related conditions and symptoms. For type II diabetes, insulin resistance, hyperinsulinemia, diabetes-induced hypertension, obesity, or damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system, a compound may be administered concurrently with a hypoglycemic compound instead of insulin. Alternatively, a compound may be administered concurrently with insulin and a hypoglycemic compound to treat type II diabetes, insulin resistance, hyperinsulinemia, diabetes-induced hypertension, obesity, or damage to blood vessels, eyes, kidneys, nerves, autonomic nervous system, skin, connective tissue, or immune system.
- “Concurrent administration” and “concurrently administering” as used herein includes administering a compound suitable for use in methods of the invention and insulin and/or a hypoglycemic compound in admixture, such as, for example, in a pharmaceutical composition, or as separate compounds, such as, for example, separate pharmaceutical compositions administered consecutively, simultaneously, or at different times. Preferably, if the compound and insulin and/or hypoglycemic compound are administered separately, they are not administered so distant in time from each other that the compound and the insulin and/or hypoglycemic compound cannot interact and a lower dosage amount of insulin and/or hypoglycemic compound cannot be administered.
- Suitable hypoglycemic compounds include, for example, metformin, acarbose, acetohexamide, glimepiride, tolazamide, glipizide, glyburide, tolbutamide, chlorpropamide, thiazolidinediones, alpha glucosidase inhibitors, biguanindine derivatives, and troglitazone, and a mixture thereof. Preferably, the hypoglycemic compound is tolbutamide.
- A physician or veterinarian of ordinary skill readily determines a subject who is exhibiting symptoms of diabetes mellitus and related conditions and symptoms. Regardless of the route of administration selected, the compound and the insulin and/or hypoglycemic compound are formulated into pharmaceutically acceptable unit dosage forms by conventional methods known to the pharmaceutical art. An effective but nontoxic quantity of the compound and the insulin and/or hypoglycemic compound is employed in the treatment of diabetes mellitus and related conditions and symptoms. The compound and the insulin may be concurrently administered parenterally in admixture or may be concurrently administered enterally and/or parenterally separately. Similarly, the compound and the hypoglycemic compound may be concurrently administered enterally in admixture or may be administered enterally and/or parenterally separately. In some instances, the compound may be concurrently administered with insulin and a hypoglycemic compound. Such administration would involve enteral and/or parenteral administration as described above.
- Parenteral administration includes subcutaneous, intramuscular, intradermal, intramammary, intravenous, and other administrative methods known in the art. Enteral administration includes tablets, sustained release tablets, enteric coated tablets, capsules, sustained release capsules, enteric coated capsules, pills, powders, granules, solutions, and the like.
- A pharmaceutical composition suitable for administration includes a pharmaceutically acceptable carrier and a compound suitable for use in methods of the invention and, optionally, insulin and/or a hypoglycemic compound. A pharmaceutically acceptable carrier includes, but is not limited to, physiological saline, ringers, phosphate buffered saline, and other carriers known in the art. Pharmaceutical compositions may also include stabilizers, antioxidants, colorants, and diluents. Pharmaceutically acceptable carriers and additives are chosen such that side effects from the pharmaceutical compound are minimized and the performance of the compound is not canceled or inhibited to such an extent that treatment is ineffective.
- Methods of preparing pharmaceutical compositions containing a pharmaceutically acceptable carrier and a compound suitable for use in methods of the invention and, optionally, insulin and/or a hypoglycemic compound, are known to those of skill in the art. All methods may include the step of bringing the compound and, optionally, a hypoglycemic compound in association with the carrier or additives. In general, the formulations are prepared by uniformly and intimately bringing the compound into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired unit dosage form.
- The ordinarily skilled physician or veterinarian will readily determine and prescribe the therapeutically effective amount of the compound to treat the disease for which treatment is administered as described above.
- When concurrently administering a compound with insulin and/or a hypoglycemic compound, the compound is administered in a range of about 0.1-100 mg per daily dose, typically 0.5-50 mg/kg of body weight per daily dose. A hypoglycemic compound is administered in a range of about 1 to 300 mg per daily dose, typically 1 to 200 mg per daily dose. Insulin is typically administered in a range of about 0.1 to 2 units/kg of a patient's body weight per daily dose. A “unit” of insulin refers to that amount of insulin necessary to lower the blood-sugar level in a rabbit by 50% in 1 to 3 hours.
- The invention is further elaborated by the representative examples as follows. Such examples are not meant to be limiting but only illustrative of the invention.
- A mixture of morpholine (20 g) and toluene (100 mL) was stirred and heated using an oil bath set to 100° C. for 15 minutes. Pyridoxal hydrochloride (10 g) was then added and the reaction mixture was stirred at 100° C. for two hours. The reaction mixture was then concentrated by distillation of the toluene and morpholine. The concentrated reaction mixture was washed three times by adding toluene (100 mL) and removing the toluene by distillation. After washing, the residue was dissolved in toluene and filtered, and then hexane was added until precipitation began, at which time the reaction mixture was left overnight at room temperature. Crystals were collected and washed thoroughly with hexane.
- Nuclear magnetic resonance spectroscopy (NMR) and mass spectroscopy confirmed the identity of the synthesized compound. The purity of the compound was analyzed by high performance liquid chromatography (HPLC) using a C-18 reverse phase column and water/acetonitrile as solvent (1-100% acetonitrile over 25 minutes).
- Anhydrous powdered potassium carbonate (5 g), acetone (100 mL), and morpholine pyridoxal-4,5-aminal (1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) (1.11 g, 5 mmoles) were mixed in a nitrogen-cooled, dry flask. The reaction mixture was cooled to between 0 and 5° C. and then p-toluoyl chloride (1.06 g, 6 mmoles) in acetone (20 mL) was added. This mixture was stirred for two hours, followed by filtering out the solid and evaporating the solution to dryness under vacuum. The residue was chromatographed on silica gel using a mixture of ethyl acetate and hexane as solvent.
- The purified solid was analyzed by thin layer chromatography (TLC), NMR, and mass spectroscopy. The purity of the synthesized compound was confirmed by HPLC as described in Example 1.
- Anhydrous potassium carbonate (10 g), acetone (100 mL), and pyridoxal hydrochloride (2.03 g, 10 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then p-toluoyl chloride (2.12 g, 12 mmoles) in acetone (20 mL) was added. The reaction mixture was stirred for two hours followed by filtering out the solid and evaporating the solution to dryness under vacuum. The residue was chromatographed on silica gel as described in Example 2.
- The purified solid was analyzed by TLC, NMR, and mass spectroscopy. The purity of the compound was confirmed by HPLC as described in Example 1.
- Alternative to the above-described method, the 3-toluate of pyridoxal is synthesized by reacting the compound of Example 2 with 80% aqueous acetic acid at 60° C. for 30 minutes, and then diluting with water and extracting by ethyl acetate. The ethyl acetate layer is washed with 5% aqueous sodium bicarbonate, dried with magnesium sulfate, and evaporated to dryness. The compound is also analyzed as described supra.
- Anhydrous powdered potassium carbonate (5 g), acetone (100 mL), and morpholine pyridoxal-4,5-aminal (1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) (1.11 g, 5 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then β-naphthoyl chloride (1.06 g, 6 mmoles) in acetone (20 mL) was added. The reaction mixture was stirred for two hours, and then the solid was filtered out and the solution was evaporated to dryness under vacuum. The residue was chromatographed according to Example 2.
- The purified solid was analyzed according to Example 2, and the purity was confirmed according to Example 1.
- Anhydrous potassium carbonate (10 g), acetone (100 mL), and pyridoxal hydrochloride (2.03 g, 10 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then β-naphthoyl chloride (2.12 g, 12 mmoles) in acetone (20 mL) was added and the mixture was stirred for two hours. The solid was filtered out and the solution was evaporated to dryness under vacuum. The residue was chromatographed according to Example 2.
- The purified solid was analyzed according to Example 2, and the purity was confirmed according to Example 1.
- Alternative to the above-described synthesis, the 3-β-naphthoate of pyridoxal is prepared by reacting the compound of Example 4 with 80% aqueous acetic acid at 60° C. for 30 minutes, followed by diluting with water and extracting by ethyl acetate. The ethyl acetate layer is then washed with 5% aqueous sodium bicarbonate, dried with magnesium sulfate, and evaporated to dryness. The compound is also analyzed as described supra.
- Anhydrous powdered potassium carbonate (5 g), acetone (100 mL), and morpholine pyridoxal-4,5-aminal (1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) (1.11 g, 5 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then pivaloyl chloride (trimethylacetyl chloride) (720 mg, 6 mmoles) in acetone (20 mL) was added. The reaction mixture was stirred for two hours. The solid was then filtered out and the solution was evaporated to dryness under vacuum. The residue was chromatographed according to Example 2.
- The purified solid was analyzed according to Example 2, and the purity was confirmed according to Example 1.
- Anhydrous powdered potassium carbonate (5 g), acetone (100 mL), and morpholine pyridoxal-4,5-aminal (1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) (1.11 g, 5 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then dimethylcarbamoyl chloride (642 mg, 6 mmoles) in acetone (20 mL) was added. The reaction mixture was stirred for two hours. The solid was then filtered out and the solution was evaporated to dryness under vacuum. The residue was chromatographed according to Example 2.
- The purified solid was analyzed according to Example 2, and the purity was confirmed according to Example 1.
- Anhydrous powdered potassium carbonate (5 g), acetone (100 mL), and morpholine pyridoxal-4,5-aminal (1-morpholino-1,3-dihydro-7-hydroxy-6-methylfuro(3,4-c)pyridine) (1.11 g, 5 mmoles) were mixed in a nitrogen-cooled, dry flask. The mixture was cooled to between 0 and 5° C. and then acetylsalicyloyl chloride (1.09 g, 6 mmoles) in acetone (20 mL) was added. The reaction mixture was stirred for two hours. The solid was then filtered out and the solution was evaporated to dryness under vacuum. The residue was chromatographed according to Example 2.
- The purified solid was analyzed according to Example 2, and the purity was confirmed according to Example 1.
- To determine the effect of a compound suitable for use in methods of the invention on glucose and insulin levels, rats are administered pyridoxal-5′-phosphate, either alone or in combination with insulin, after being experimentally induced with type I diabetes, and their urine and blood glucose and insulin levels are determined.
- Male Sprague-Dawley (Charles River Laboratories, Montreal, Canada) rats weighing approximately 200 g are randomly separated into control and experimental groups. All experimental animals are given an intravenous injection of 0.1 M citrate buffered streptozotocin (pH 4.5) at a dosage of 65 mg/kg of body weight to induce diabetes mellitus. All control animals receive an intravenous injection of 0.1 M citrate buffer (pH 4.5) alone.
- One experimental group of rats also receives daily doses of pyridoxal-5′-phosphate (25 mg/kg body weight) (Aldrich Canada Ltd., Ontario, Canada). A second experimental group receives daily subcutanteous injections of Humulin® N (3 units per day) (insulin isophene, human biosynthetic; Eli Lilly and Co., Indianapolis, Ind.). A third experimental group receives both daily subcutaneous injections of Humulin® N (3 units per day) and a daily dose of pyridoxal-5′-phosphate (25 mg/kg body weight). A fourth experimental group receives daily subcutaneous injections of Humulin® N (1.5 units per day). A fifth experimental group receives both daily subcutaneous injections of Humulin® N (1.5 units per day) and a daily dose of pyridoxal-5′-phosphate (25 mg/kg body weight).
- All animals are fed rat chow and water ad libitum. Plasma glucose levels were done using the Infinity Glucose Reagent® (Sigma Diagnostics, St. Louis, Mo.).
- The experimental group of rats that receive daily doses of pyridoxal-5′-phosphate and daily injections of Humulin® N show reduced levels of glucose and insulin in blood and urine samples when compared with the group of rats that receive daily injections of Humulin® N without receiving daily doses of pyridoxal-5′-phosphate.
- FIG. 1 demonstrates the effect of P-5-P and insulin alone or in combination on increased plasma glucose levels in a Type I diabetes indication of hyperglycemia. It can be seen in FIG. 1 that Insulin (1 unit and 3 unit) and P-5-P significantly reduced the plasma glucose levels when compared to diabetic group. Moreover a decreased dose of insulin was needed in the presence of P-5-P to produce the same effect as with a full dose of 3 units of insulin.
- FIG. 2 demonstrates the effect of P-5-P and insulin alone or in combination on plasma glucose levels in a Type I diabetes indication of hyperglycemia. It can be seen in FIG. 2 that Insulin (1 unit and 3 unit) and P-5-P significantly increased the plasma insulin levels when compared to diabetic group. Moreover a decreased dose of insulin was needed in the presence of P-5-P to produce the same effect as with a full dose of 3 units of insulin.
- To determine the effect of a compound suitable for use in methods of the invention on glucose and insulin levels, as well as increases in systolic blood pressure, rats having type II diabetes are administered pyridoxal-5′-phosphate, either alone or in combination with sucrose and/or tolbutamide, and their systolic blood pressure, urine and blood glucose and insulin levels are determined. Acarbose reduces blood pressure in sucrose induced hypertension in rats. Madar Z et al: Isr J Med Sci; 33:153-159.
- As described by Madar et al.,Acarbose reduces blood pressure in sucrose induced hypertension in rats. Madar Z et al: Isr J Med Sci; 33:153-159, a high sucrose or fructose diet for a prolonged period is one technique used to induce Type II diabetes, specifically hypertension associated with hyperglycemia and hyperinsulinemia in animals.
- Male Sprague-Dawley (Charles River Laboratories, Montreal, Canada) rats weighing approximately 200 g are randomly separated into the following groups with each group having 5 amimals:
- a) The control group that was fed a normal diet and provided with drinking water
- b) The sucrose group that was fed 35% sucrose (35 gm sucrose/100 ml of drinking water/day) with an average intake of 150 ml/rat/day
- c) The sucrose+P-5-P group that was fed sucrose as stated in b above and 25 mg/kg orally/day of P-5-P
- d) The sucrose+tolbutamide group that was fed sucrose as stated in b above and administered 40 mg/kg orally/day of tolbutamide
- e) The sucrose+P-5-P+tolbutamide group that was fed sucrose as stated in b above, 25 mg/kg orally/day of P-5-P, and administered 40 mg/kg orally/day of tolbutamide
- f) The sucrose+P-5-P+tolbutamide group that was fed sucrose as stated in b above, 25 mg/kg orally/day of P-5-P, and administered 20 mg/kg, orally/day of tolbutamide
- g) The sucrose+tolbutamide group that was fed sucrose as stated in b above and 20 mg/kg orally/day of tolbutamide.
- Total duration of the study was 16 weeks. Plasma insulin levels were measured using Rat Insulin RIA Kit (Linco Research Inc., St. Charles, Mo.). Plasma glucose levels were done using the Infinity Glucose Reagent® (Sigma Diagnostics, St. Louis, Mo.). Blood pressure was measured using the tail cuff method, (see, Madar et al.,Acarbose reduces blood pressure in sucrose induced hypertension in rats. Madar Z et al: Isr J Med Sci; 33:153-159).
- FIG. 3 demonstrates the effect of P-5-P and tolbutamide alone or in combination on increased plasma glucose levels in a Type II diabetes indication of hyperglycemia. It can be seen in FIG. 3 that tolbutamide (40 and 20 mg/kg) and P-5-P significantly decreased the plasma glucose levels when compared to diabetic group. Moreover a decreased dose of tolbutamide was needed in the presence of P-5-P to produce the same effect as with a full dose of 40 mg/kg tolbutamide.
- FIG. 4 demonstrates the effect of P-5-P and tolbutamide alone or in combination on increased plasma insulin levels in a Type II diabetes indication of hyperglycemia. It can be seen in FIG. 4 that tolbutamide (40 and 20 mg/kg) and P-5-P significantly decreased the plasma insulin levels when compared to diabetic group. Moreover a decreased dose of tolbutamide was needed in the presence of P-5-P to produce the same or better effect as with a full dose of 40 mg/kg tolbutamide.
- FIG. 5 demonstrates the effect of P-5-P and tolbutamide alone or in combination on increased systolic blood pressure in a Type II diabetes indication of hyperglycemia. It can be seen in FIG. 5 that that P-5-P significantly decreased the rise in systolic blood pressure when compared to diabetic and tolbutamide treatment groups. Moreover when the rats were treated with P-5-P and tolbutamide (40 mg/kg), the decrease in systolic blood pressure was significantly greater when compared to rats treated with P-5-P or tolbutamide alone.
- It should be noted that, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a composition containing “a compound” includes a mixture of two or more compounds. Similarly, reference to “a compound” includes a mixture having more than one compound.
- Although embodiments of the invention have been described above, it is not limited thereto, and it will be apparent to persons skilled in the art that numerous modifications and variations form part of the present invention insofar as they do not depart from the spirit, nature, and scope of the claimed and described invention.
Claims (13)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/881,864 US20040235907A1 (en) | 1999-07-13 | 2004-06-30 | Treatment of diabetes and related pathologies |
US11/931,672 US20090018052A1 (en) | 1999-07-13 | 2007-10-31 | Treatment of Diabetes and Related Pathologies |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14346699P | 1999-07-13 | 1999-07-13 | |
US09/615,201 US6489345B1 (en) | 1999-07-13 | 2000-07-13 | Treatment of diabetes and related pathologies |
US10/215,739 US20030008847A1 (en) | 1999-07-13 | 2002-08-08 | Treatment of diabetes and related pathologies |
US10/881,864 US20040235907A1 (en) | 1999-07-13 | 2004-06-30 | Treatment of diabetes and related pathologies |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/215,739 Continuation US20030008847A1 (en) | 1999-07-13 | 2002-08-08 | Treatment of diabetes and related pathologies |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/931,672 Continuation US20090018052A1 (en) | 1999-07-13 | 2007-10-31 | Treatment of Diabetes and Related Pathologies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040235907A1 true US20040235907A1 (en) | 2004-11-25 |
Family
ID=22504214
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/615,201 Expired - Fee Related US6489345B1 (en) | 1999-07-13 | 2000-07-13 | Treatment of diabetes and related pathologies |
US10/215,739 Abandoned US20030008847A1 (en) | 1999-07-13 | 2002-08-08 | Treatment of diabetes and related pathologies |
US10/881,864 Abandoned US20040235907A1 (en) | 1999-07-13 | 2004-06-30 | Treatment of diabetes and related pathologies |
US11/931,672 Abandoned US20090018052A1 (en) | 1999-07-13 | 2007-10-31 | Treatment of Diabetes and Related Pathologies |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/615,201 Expired - Fee Related US6489345B1 (en) | 1999-07-13 | 2000-07-13 | Treatment of diabetes and related pathologies |
US10/215,739 Abandoned US20030008847A1 (en) | 1999-07-13 | 2002-08-08 | Treatment of diabetes and related pathologies |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/931,672 Abandoned US20090018052A1 (en) | 1999-07-13 | 2007-10-31 | Treatment of Diabetes and Related Pathologies |
Country Status (5)
Country | Link |
---|---|
US (4) | US6489345B1 (en) |
EP (1) | EP1196171A2 (en) |
AU (1) | AU5840200A (en) |
CA (1) | CA2376029A1 (en) |
WO (1) | WO2001003682A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030008847A1 (en) * | 1999-07-13 | 2003-01-09 | Medicure, Inc. | Treatment of diabetes and related pathologies |
US20040171588A1 (en) * | 2000-02-29 | 2004-09-02 | Wasimul Haque | Cardioprotective phosphonates and malonates |
US20040220090A1 (en) * | 1995-09-12 | 2004-11-04 | Kansas University Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US20060148763A1 (en) * | 2005-01-05 | 2006-07-06 | Friesen Albert D | Compounds and methods for regulating triglyceride levels |
US20070032456A1 (en) * | 2003-03-27 | 2007-02-08 | Friesen Albert D | Modulation of cell death |
US20070243249A1 (en) * | 2004-11-26 | 2007-10-18 | Friesen Albert D | Novel formulation of pyridoxal-5'-phosphate and method of preparation |
US20080213364A1 (en) * | 2004-11-26 | 2008-09-04 | Medicure International, Inc. | Formulations of Pyridoxal-5'-Phosphate and Methods of Preparation |
US7425570B2 (en) | 2000-07-07 | 2008-09-16 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US20090018106A1 (en) * | 2005-03-30 | 2009-01-15 | Medicure International Inc. | Intravenous formulations of pyridoxal 5'- phosphate and method of preparation |
US7812037B2 (en) | 2004-10-28 | 2010-10-12 | Medicure International, Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1608379A1 (en) * | 2003-03-27 | 2005-12-28 | Medicure Inc. | Compositions for treating angina |
US20090082407A1 (en) * | 2004-06-18 | 2009-03-26 | Biostratum, Inc. | Pyridoxamine for the Treatment of Diabetic Kidney Disease |
PL1643999T3 (en) * | 2003-06-20 | 2012-02-29 | Nephrogenex Inc | Pyridoxamine for use in the treatment of diabetic neprhopathy in type ii diabetes |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
WO2005077902A2 (en) * | 2004-02-09 | 2005-08-25 | Biostratum, Inc. | Methods for the synthesis of pyridoxamine |
US20080032952A1 (en) * | 2004-07-09 | 2008-02-07 | Marjorie Zettler | Combination Therapies Employing Nicotinic Acid Derivatives or Fibric Acid Derivatives |
AU2005271526B2 (en) * | 2004-08-03 | 2011-12-08 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
CA2575849A1 (en) * | 2004-08-10 | 2006-02-16 | Medicure International Inc. | Combination therapies employing vitamin b6 related compounds and ace inhibitors and uses thereof for the treatment of diabetic disorders |
US7459468B2 (en) | 2004-10-28 | 2008-12-02 | Medicure International, Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
US20070015839A1 (en) * | 2005-07-14 | 2007-01-18 | Franco Folli | Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome |
US20070249562A1 (en) * | 2006-04-25 | 2007-10-25 | Friesen Albert D | Treatment of atrial fibrillation |
Citations (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3206463A (en) * | 1965-09-14 | Pyridoxine aspartate and its process of preparation | ||
US3282778A (en) * | 1960-09-02 | 1966-11-01 | Lohel Mervyn Joseph | Medicinal preparation containing acetyl salicylic acid and a pyridoxine compound |
US3910921A (en) * | 1970-01-08 | 1975-10-07 | Soc D Etudes Prod Chimique | Papaverine monopyridoxal phosphate |
US3987177A (en) * | 1974-06-27 | 1976-10-19 | Synthelabo | Vincaminic acid esters |
US4032534A (en) * | 1973-03-22 | 1977-06-28 | Ferlus-Chimie S.A. | Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids |
US4036844A (en) * | 1972-04-04 | 1977-07-19 | Beecham Group Limited | Aryloxypyridines |
US4053607A (en) * | 1972-04-04 | 1977-10-11 | Beecham Group Limited | Aryloxypyridine for treating hyperglycaemia |
US4137316A (en) * | 1976-05-11 | 1979-01-30 | Societe D'etudes De Produits Chimiques | Anti-depressive vincamine pyridoxal-5-phosphate |
US4167562A (en) * | 1978-08-28 | 1979-09-11 | Evers H Ray | Method and composition for treating arteriosclerosis |
US4361570A (en) * | 1980-09-22 | 1982-11-30 | Istituto Luso Farmaco D'italia S.P.A. | Use of pyridoxine α-ketoglutarate in the prophylaxis of hyperlacticacidaemia |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4605741A (en) * | 1985-11-13 | 1986-08-12 | Lisapharma Spa | Pharmaceutically active salt derivative of 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate |
US4730042A (en) * | 1985-06-01 | 1988-03-08 | Basf Aktiengesellschaft | Compounds 1 or 3-hydroxy-4-benzyl-6-methyl-7-(4-isopropylamino-butoxy)-1,3-dihydro[3,4-C]pyridine and 2-methyl-3-(4-isopropyl-aminobutoxy)-4-(1'-morphilinomethyl)-5-hydroxymethyl-6-benzyl pyridine, useful for treating cardiac arrhythmias |
US4735950A (en) * | 1983-04-05 | 1988-04-05 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) | Furo-(3,4-C)-pyridine derivatives and therapeutic composition containing the same |
US4837239A (en) * | 1985-08-23 | 1989-06-06 | Syntex (U.S.A.) Inc. | Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins |
US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
US4962121A (en) * | 1987-04-22 | 1990-10-09 | Anders Hamberger | Method and composition for treating neurological diseases such as migraine |
US5001115A (en) * | 1989-05-17 | 1991-03-19 | University Of Florida | Prodrugs of biologically active hydroxyaromatic compounds |
US5053396A (en) * | 1985-08-27 | 1991-10-01 | Blass David H | Therapeutic composition |
US5118505A (en) * | 1988-01-28 | 1992-06-02 | Koeltringer Peter | Combination preparation for the treatment of nerve cell and nerve fibre diseases and injury |
US5130324A (en) * | 1984-03-19 | 1992-07-14 | The Rockefeller University | 2-alkylidene-aminoguanidines and methods of use therefor |
US5132115A (en) * | 1986-04-17 | 1992-07-21 | Karin Wolter | Planar therapeutic system, process for its production and utilization |
US5210083A (en) * | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
US5213813A (en) * | 1987-05-29 | 1993-05-25 | The University Of Vermont | Pyridoxal-5'-phosphate as an in vitro blood platelet stabilizer |
US5254572A (en) * | 1987-11-27 | 1993-10-19 | Vesta Medicines (Pty) Ltd. | Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed |
US5254557A (en) * | 1988-05-09 | 1993-10-19 | Beecham Group P.L.C. | Compound and treatment |
US5272165A (en) * | 1984-03-19 | 1993-12-21 | The Rockefeller University | 2-alkylidene-aminoguanidines and methods of use therefor |
US5278154A (en) * | 1991-07-03 | 1994-01-11 | Adir Et Compagnie | New vanadium complexes |
US5288716A (en) * | 1987-02-18 | 1994-02-22 | Ulrich Speck | Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis |
US5326757A (en) * | 1992-01-06 | 1994-07-05 | Health Maintenance Programs, Inc. | Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty |
US5328453A (en) * | 1988-12-21 | 1994-07-12 | Drug Delivery Systems Inc. | Method for enhancing transdermal drug delivery of electrical drug applicators |
US5372999A (en) * | 1990-05-25 | 1994-12-13 | Steigerwald Arzneimittelwerk Gmbh | Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which result from vascular lesions |
US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
US5420112A (en) * | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
US5441972A (en) * | 1993-04-02 | 1995-08-15 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical use of pyridoxal derivative |
US5504090A (en) * | 1994-03-30 | 1996-04-02 | Trustees Of The University Of Pennsylvania | Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury |
US5563126A (en) * | 1986-11-20 | 1996-10-08 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
US5569648A (en) * | 1992-06-12 | 1996-10-29 | Cephalon, Inc. | Prevention and treatment of peripheral neuropathy |
US5569459A (en) * | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
US5631271A (en) * | 1986-11-29 | 1997-05-20 | Serfontein; Willem J. | Methods and preparations for the treatment and prophylaxis of metabolic disturbances |
US5728684A (en) * | 1991-05-15 | 1998-03-17 | Yale University | Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
US5733884A (en) * | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US5733916A (en) * | 1995-03-24 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
US5770215A (en) * | 1997-01-06 | 1998-06-23 | Moshyedi; Emil Payman | Multivitamin/vascular occlusion inhibiting composition |
US5795873A (en) * | 1992-12-29 | 1998-08-18 | Metabolite Laboratories, Inc. | Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6 |
US5804163A (en) * | 1992-11-12 | 1998-09-08 | Magnetic Research, Inc. | Contrast agents for magnetic resonance imaging aminosaccharide |
US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
US5833998A (en) * | 1995-11-06 | 1998-11-10 | The Procter & Gamble Company | Topical compositions for regulating the oily/shiny appearance of skin |
US5834446A (en) * | 1996-06-21 | 1998-11-10 | Queen's University At Kingston | Nerve process growth modulators |
US5840685A (en) * | 1988-03-11 | 1998-11-24 | Teikoku Seiyaku Co., Ltd. | Intravaginal delivery of biologically active polypeptides |
US5847008A (en) * | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
US5858017A (en) * | 1994-12-12 | 1999-01-12 | Omeros Medical Systems, Inc. | Urologic irrigation solution and method for inhibition of pain, inflammation and spasm |
US5874420A (en) * | 1995-12-26 | 1999-02-23 | Allegheny University Of The Health Sciences | Process for regulating vagal tone |
US5874443A (en) * | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5888514A (en) * | 1997-05-23 | 1999-03-30 | Weisman; Bernard | Natural composition for treating bone or joint inflammation |
US5985857A (en) * | 1995-09-12 | 1999-11-16 | Kansas University Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
US6051587A (en) * | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
US6103748A (en) * | 1998-06-19 | 2000-08-15 | Bryan; Thomas B. | Method of treating an autoimmune disorder |
US6228858B1 (en) * | 1995-09-12 | 2001-05-08 | University Of Kansas Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US6339085B1 (en) * | 1999-03-08 | 2002-01-15 | The University Of Manitoba | Therapeutics for cardiovascular and related diseases |
US6342500B1 (en) * | 1999-03-05 | 2002-01-29 | Kansas University Medical Center | Post-Amadori inhibitors of Advanced Glycation reactions |
US6417204B1 (en) * | 2000-07-07 | 2002-07-09 | Medicure International Inc. | Pyridoxine AMD pyridoxal analogues: cardiovascular therapeutics |
US6489345B1 (en) * | 1999-07-13 | 2002-12-03 | Medicure, Inc. | Treatment of diabetes and related pathologies |
US6548519B1 (en) * | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
US6586414B2 (en) * | 2000-03-28 | 2003-07-01 | Medicure International Inc. | Treatment of cerebrovascular disease |
US6605612B2 (en) * | 2000-02-29 | 2003-08-12 | Medicure International Inc. | Cardioprotective phosohonates and malonates |
US6677356B1 (en) * | 1999-08-24 | 2004-01-13 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US6897228B2 (en) * | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR846376A (en) | 1938-08-23 | 1939-09-15 | Air navigation and aerial bombardment equipment | |
GB966805A (en) | 1961-05-15 | 1964-08-19 | Merck & Co Inc | Process for the preparation of 2-methyl-3-hydroxypyridines |
NL280553A (en) | 1962-07-05 | |||
GB1228142A (en) | 1967-03-31 | 1971-04-15 | ||
DE1767499A1 (en) | 1968-05-16 | 1971-09-09 | Merck Patent Gmbh | Process for the production of durable vitamin preparations |
ES360566A1 (en) | 1968-11-22 | 1970-10-16 | Made Labor Sa | Pyridoxine alpha-ketoglutarate and derivatives thereof |
GB1236531A (en) | 1969-02-12 | 1971-06-23 | Soc D Etudes Prod Chimique | Adenin derivative |
GB1297080A (en) | 1970-04-17 | 1972-11-22 | ||
FR2101010A1 (en) | 1970-08-06 | 1972-03-31 | Lyocentre | Sparteine mono-and dipyridoxinates and prepn - as tonics for cardiova disorders |
GB1493993A (en) | 1975-05-16 | 1977-12-07 | Howard A | Dietary supplement and dietary methods employing said supplement for the treatment of obesity |
GB1360536A (en) | 1972-04-25 | 1974-07-17 | Soc D Etudes Prod Chimique | Pyridoxyl-l-aspartic acid salt |
BE790118A (en) | 1972-10-09 | 1973-02-01 | Made Labor Sa | PYRIDOXAL AND PYRIDOXAMINE ALPHA-CETOGLUTARATE DERIVATIVES, |
FR2255883A1 (en) | 1973-12-28 | 1975-07-25 | Centre Etd Ind Pharma | Clofibric acid-vitamin B6 compsns. - with synergistic hypocholesterolaemic and normolipaemic activity |
FR2275209A1 (en) | 1974-06-21 | 1976-01-16 | Synthelabo | Oxoalkyl esters of vincamine acids - and their pharm. acceptable salts for use in medicine |
DE2461742C2 (en) | 1974-12-28 | 1983-01-27 | Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt | Pyridoxine-5'-phosphoric acid ester derivatives and their preparation and pharmaceuticals containing these compounds |
DE2717478C2 (en) * | 1977-04-20 | 1984-08-16 | Basf Ag, 6700 Ludwigshafen | Process for the preparation of pyridoxine |
JPS5417130A (en) | 1977-07-08 | 1979-02-08 | Chugai Pharmaceut Co Ltd | Remedy for cardio-vasocular diseases |
BE863754A (en) | 1978-02-08 | 1978-05-29 | Dechamps Pierre | NEW VINCAMINE DERIVATIVES FOR USE AS BRAIN CIRCULATION REGULATORS |
FR2428640A1 (en) | 1978-06-12 | 1980-01-11 | Parcor | 5-Piperazino:alkoxy:methyl-pyridine cpds. - with antiinflammatory, diuretic and vaso-protective properties |
IL62602A (en) | 1980-05-19 | 1984-06-29 | Labaz Sanofi Nv | Pyridoxine derivatives,their preparation and pharmaceutical compositions containing them |
CA1184499A (en) | 1981-06-29 | 1985-03-26 | David C. Madsen | Nutritional composition for management of hepatic failure |
US4528197A (en) | 1983-01-26 | 1985-07-09 | Kabivitrum Ab | Controlled triglyceride nutrition for hypercatabolic mammals |
IN160104B (en) | 1983-04-05 | 1987-06-27 | Scras | |
US4515771A (en) | 1983-04-11 | 1985-05-07 | Fine Daniel H | Composition and method for the preventative treatment of dental disease and apparatus for dispensing said composition |
US4513771A (en) * | 1983-11-07 | 1985-04-30 | General Motors Corporation | Air valve |
GB8330517D0 (en) | 1983-11-16 | 1983-12-21 | Scras | 6-vinyl-furo-(3,4-c)pyridine derivatives |
GB8330658D0 (en) | 1983-11-17 | 1983-12-29 | Scras | 7-carboxymethoxy-furo-(3,4-c)-pyridine derivatives |
IT1212792B (en) | 1983-11-30 | 1989-11-30 | Egidio Aldo Moja | DIETARY SUPPLEMENT AND PRE-PACKED FOOD THAT CONTAINS IT PREPARATION PROCEDURE AND METHOD OF ADMINISTRATION |
US4567179A (en) | 1984-10-11 | 1986-01-28 | Pfizer, Inc. | Antiinflammatory salts of piroxicam |
US4735956A (en) | 1985-09-13 | 1988-04-05 | Merck & Co., Inc. | Certain 1,4-dihydro-2,6-di-lower hydrocarbyl-4-heterocyclic-3,5-pyridine dicarboxylates which are useful as calcium channel blockers |
NZ222664A (en) | 1986-11-29 | 1990-06-26 | Vesta Med Pty Ltd | Pharmaceutical compositions containing pyridoxal as a source of vitamin b6 |
DE3705549A1 (en) | 1987-02-18 | 1988-09-01 | Ulrich Speck | USE OF PYRIDOXINE DERIVATIVES IN THE PROPHYLAXIS AND THERAPY OF HYPERLIPIDAEMIA AND ATHEROSCLEROSIS |
FR2641189B1 (en) | 1988-06-20 | 1991-05-10 | Timol Mamoojee | PHARMACEUTICAL COMPOSITIONS CONTAINING ACETYL SALICYLIC ACID AND VITAMIN B6 |
GB8918368D0 (en) | 1989-08-11 | 1989-09-20 | Amco Chemie Gmbh | Compositions for treating obstructive airways disease |
GB2254556B (en) | 1991-04-11 | 1995-04-12 | Fisons Plc | Formulations containing linolenic acid |
IT1263957B (en) | 1993-02-23 | 1996-09-05 | THERAPEUTIC USE OF PYROLIDON CARBOXYLATE OF PYRIDOXY | |
DE4344751A1 (en) | 1993-12-28 | 1995-06-29 | Carl Heinrich Dr Weischer | New vitamin=B6 ester cpds. of sulphur-contg. carboxylic acids |
US7030146B2 (en) * | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
EP0891719A1 (en) | 1997-07-14 | 1999-01-20 | N.V. Nutricia | Nutritional composition containing methionine |
SE516023C2 (en) * | 1999-06-24 | 2001-11-12 | Abb Ab | Industrial robot comprising an gearbox configuration and method in an industrial robot |
WO2001003692A1 (en) * | 1999-07-09 | 2001-01-18 | Oregon Health Sciences University | Compositions and methods for promoting nerve regeneration |
US7442689B2 (en) * | 2000-02-29 | 2008-10-28 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US20040121988A1 (en) * | 2001-03-28 | 2004-06-24 | Medicure International Inc. | Treatment of cerebrovascular disease |
US20040186077A1 (en) * | 2003-03-17 | 2004-09-23 | Medicure International Inc. | Novel heteroaryl phosphonates as cardioprotective agents |
EP1608379A1 (en) * | 2003-03-27 | 2005-12-28 | Medicure Inc. | Compositions for treating angina |
EP1610783A2 (en) * | 2003-03-27 | 2006-01-04 | Medicure Inc. | Modulation of cell death |
WO2006002549A1 (en) * | 2004-07-07 | 2006-01-12 | Medicure International Inc. | Combination therapies employing platelet aggregation drugs |
CA2575849A1 (en) * | 2004-08-10 | 2006-02-16 | Medicure International Inc. | Combination therapies employing vitamin b6 related compounds and ace inhibitors and uses thereof for the treatment of diabetic disorders |
US20070060549A1 (en) * | 2004-08-10 | 2007-03-15 | Friesen Albert D | Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
US7459468B2 (en) * | 2004-10-28 | 2008-12-02 | Medicure International, Inc. | Aryl sulfonic pyridoxines as antiplatelet agents |
AU2005304220A1 (en) * | 2004-10-28 | 2006-05-18 | Medicure International Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
US20060094749A1 (en) * | 2004-10-28 | 2006-05-04 | Medicure International Inc. | Substituted pyridoxines as anti-platelet agents |
US20070243249A1 (en) * | 2004-11-26 | 2007-10-18 | Friesen Albert D | Novel formulation of pyridoxal-5'-phosphate and method of preparation |
JP2008526783A (en) * | 2005-01-05 | 2008-07-24 | メディキュア・インターナショナル・インコーポレーテッド | Compounds and methods for modulating triglyceride levels |
CA2632090A1 (en) * | 2005-11-28 | 2007-05-31 | Medicure International Inc. | Selected dosage for the treatment of cardiovascular and related pathologies |
US20070249562A1 (en) * | 2006-04-25 | 2007-10-25 | Friesen Albert D | Treatment of atrial fibrillation |
-
2000
- 2000-07-13 CA CA002376029A patent/CA2376029A1/en not_active Abandoned
- 2000-07-13 US US09/615,201 patent/US6489345B1/en not_active Expired - Fee Related
- 2000-07-13 AU AU58402/00A patent/AU5840200A/en not_active Abandoned
- 2000-07-13 WO PCT/IB2000/001041 patent/WO2001003682A2/en not_active Application Discontinuation
- 2000-07-13 EP EP00944170A patent/EP1196171A2/en not_active Withdrawn
-
2002
- 2002-08-08 US US10/215,739 patent/US20030008847A1/en not_active Abandoned
-
2004
- 2004-06-30 US US10/881,864 patent/US20040235907A1/en not_active Abandoned
-
2007
- 2007-10-31 US US11/931,672 patent/US20090018052A1/en not_active Abandoned
Patent Citations (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3206463A (en) * | 1965-09-14 | Pyridoxine aspartate and its process of preparation | ||
US3282778A (en) * | 1960-09-02 | 1966-11-01 | Lohel Mervyn Joseph | Medicinal preparation containing acetyl salicylic acid and a pyridoxine compound |
US3910921A (en) * | 1970-01-08 | 1975-10-07 | Soc D Etudes Prod Chimique | Papaverine monopyridoxal phosphate |
US4036844A (en) * | 1972-04-04 | 1977-07-19 | Beecham Group Limited | Aryloxypyridines |
US4053607A (en) * | 1972-04-04 | 1977-10-11 | Beecham Group Limited | Aryloxypyridine for treating hyperglycaemia |
US4032534A (en) * | 1973-03-22 | 1977-06-28 | Ferlus-Chimie S.A. | Certain 2-(2-thioethyl)thiazolidine-4-carboxylic acids |
US3987177A (en) * | 1974-06-27 | 1976-10-19 | Synthelabo | Vincaminic acid esters |
US4137316A (en) * | 1976-05-11 | 1979-01-30 | Societe D'etudes De Produits Chimiques | Anti-depressive vincamine pyridoxal-5-phosphate |
US4167562A (en) * | 1978-08-28 | 1979-09-11 | Evers H Ray | Method and composition for treating arteriosclerosis |
US4361570A (en) * | 1980-09-22 | 1982-11-30 | Istituto Luso Farmaco D'italia S.P.A. | Use of pyridoxine α-ketoglutarate in the prophylaxis of hyperlacticacidaemia |
US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4735950A (en) * | 1983-04-05 | 1988-04-05 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S) | Furo-(3,4-C)-pyridine derivatives and therapeutic composition containing the same |
US5130324A (en) * | 1984-03-19 | 1992-07-14 | The Rockefeller University | 2-alkylidene-aminoguanidines and methods of use therefor |
US5272165A (en) * | 1984-03-19 | 1993-12-21 | The Rockefeller University | 2-alkylidene-aminoguanidines and methods of use therefor |
US4730042A (en) * | 1985-06-01 | 1988-03-08 | Basf Aktiengesellschaft | Compounds 1 or 3-hydroxy-4-benzyl-6-methyl-7-(4-isopropylamino-butoxy)-1,3-dihydro[3,4-C]pyridine and 2-methyl-3-(4-isopropyl-aminobutoxy)-4-(1'-morphilinomethyl)-5-hydroxymethyl-6-benzyl pyridine, useful for treating cardiac arrhythmias |
US4837239A (en) * | 1985-08-23 | 1989-06-06 | Syntex (U.S.A.) Inc. | Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins |
US5053396A (en) * | 1985-08-27 | 1991-10-01 | Blass David H | Therapeutic composition |
US4605741A (en) * | 1985-11-13 | 1986-08-12 | Lisapharma Spa | Pharmaceutically active salt derivative of 3-hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde phosphate |
US5132115A (en) * | 1986-04-17 | 1992-07-21 | Karin Wolter | Planar therapeutic system, process for its production and utilization |
US5210083A (en) * | 1986-07-17 | 1993-05-11 | Ed. Geistlich Sohne A.G. Fur Chemische Industrie | Pharmaceutical compositions |
US5563126A (en) * | 1986-11-20 | 1996-10-08 | Metabolite Laboratories | Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6 |
US5631271A (en) * | 1986-11-29 | 1997-05-20 | Serfontein; Willem J. | Methods and preparations for the treatment and prophylaxis of metabolic disturbances |
US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
US5288716A (en) * | 1987-02-18 | 1994-02-22 | Ulrich Speck | Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis |
US4962121A (en) * | 1987-04-22 | 1990-10-09 | Anders Hamberger | Method and composition for treating neurological diseases such as migraine |
US5213813A (en) * | 1987-05-29 | 1993-05-25 | The University Of Vermont | Pyridoxal-5'-phosphate as an in vitro blood platelet stabilizer |
US5254572A (en) * | 1987-11-27 | 1993-10-19 | Vesta Medicines (Pty) Ltd. | Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed |
US5118505A (en) * | 1988-01-28 | 1992-06-02 | Koeltringer Peter | Combination preparation for the treatment of nerve cell and nerve fibre diseases and injury |
US5840685A (en) * | 1988-03-11 | 1998-11-24 | Teikoku Seiyaku Co., Ltd. | Intravaginal delivery of biologically active polypeptides |
US5254557A (en) * | 1988-05-09 | 1993-10-19 | Beecham Group P.L.C. | Compound and treatment |
US5328453A (en) * | 1988-12-21 | 1994-07-12 | Drug Delivery Systems Inc. | Method for enhancing transdermal drug delivery of electrical drug applicators |
US5001115A (en) * | 1989-05-17 | 1991-03-19 | University Of Florida | Prodrugs of biologically active hydroxyaromatic compounds |
US5372999A (en) * | 1990-05-25 | 1994-12-13 | Steigerwald Arzneimittelwerk Gmbh | Use of magnesium-pyridoxal-5'-phosphate-glutaminate for the prevention of diseases which result from vascular lesions |
US5385937A (en) * | 1991-04-10 | 1995-01-31 | Brigham & Women's Hospital | Nitrosation of homocysteine as a method for treating homocysteinemia |
US5728684A (en) * | 1991-05-15 | 1998-03-17 | Yale University | Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
US5278154A (en) * | 1991-07-03 | 1994-01-11 | Adir Et Compagnie | New vanadium complexes |
US5326757A (en) * | 1992-01-06 | 1994-07-05 | Health Maintenance Programs, Inc. | Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty |
US5648335A (en) * | 1992-06-12 | 1997-07-15 | Cephalon, Inc. | Prevention and treatment of peripheral neuropathy |
US5569648A (en) * | 1992-06-12 | 1996-10-29 | Cephalon, Inc. | Prevention and treatment of peripheral neuropathy |
US5633228A (en) * | 1992-06-12 | 1997-05-27 | Cephalon, Inc., | Prevention and treatment of peripheral neuropathy |
US5420112A (en) * | 1992-06-12 | 1995-05-30 | Lewis; Michael E. | Prevention and treatment of peripheral neuropathy |
US5804163A (en) * | 1992-11-12 | 1998-09-08 | Magnetic Research, Inc. | Contrast agents for magnetic resonance imaging aminosaccharide |
US5795873A (en) * | 1992-12-29 | 1998-08-18 | Metabolite Laboratories, Inc. | Method for treatment and prevention of deficiencies of vitamins B12, folic acid and B6 |
US5441972A (en) * | 1993-04-02 | 1995-08-15 | Senju Pharmaceutical Co., Ltd. | Pharmaceutical use of pyridoxal derivative |
US5504090A (en) * | 1994-03-30 | 1996-04-02 | Trustees Of The University Of Pennsylvania | Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury |
US5858017A (en) * | 1994-12-12 | 1999-01-12 | Omeros Medical Systems, Inc. | Urologic irrigation solution and method for inhibition of pain, inflammation and spasm |
US5569459A (en) * | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
US5733916A (en) * | 1995-03-24 | 1998-03-31 | The Trustees Of The University Of Pennsylvania | Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
US6228858B1 (en) * | 1995-09-12 | 2001-05-08 | University Of Kansas Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US5985857A (en) * | 1995-09-12 | 1999-11-16 | Kansas University Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US5874443A (en) * | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
US5833998A (en) * | 1995-11-06 | 1998-11-10 | The Procter & Gamble Company | Topical compositions for regulating the oily/shiny appearance of skin |
US5733884A (en) * | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
US5874420A (en) * | 1995-12-26 | 1999-02-23 | Allegheny University Of The Health Sciences | Process for regulating vagal tone |
US5847008A (en) * | 1996-02-02 | 1998-12-08 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
US5834446A (en) * | 1996-06-21 | 1998-11-10 | Queen's University At Kingston | Nerve process growth modulators |
US5770215A (en) * | 1997-01-06 | 1998-06-23 | Moshyedi; Emil Payman | Multivitamin/vascular occlusion inhibiting composition |
US5804594A (en) * | 1997-01-22 | 1998-09-08 | Murad; Howard | Pharmaceutical compositions and methods for improving wrinkles and other skin conditions |
US5888514A (en) * | 1997-05-23 | 1999-03-30 | Weisman; Bernard | Natural composition for treating bone or joint inflammation |
US6051587A (en) * | 1998-04-16 | 2000-04-18 | Medicure, Inc. | Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein |
US6103748A (en) * | 1998-06-19 | 2000-08-15 | Bryan; Thomas B. | Method of treating an autoimmune disorder |
US6274612B1 (en) * | 1998-06-19 | 2001-08-14 | Thomas B. Bryan | Method of treating an autoimmune disorder |
US6043259A (en) * | 1998-07-09 | 2000-03-28 | Medicure Inc. | Treatment of cardiovascular and related pathologies |
US6342500B1 (en) * | 1999-03-05 | 2002-01-29 | Kansas University Medical Center | Post-Amadori inhibitors of Advanced Glycation reactions |
US6890943B2 (en) * | 1999-03-08 | 2005-05-10 | Medicure Inc. | Pyridoxal analogues and methods of treatment |
US7230009B2 (en) * | 1999-03-08 | 2007-06-12 | Medicure, Inc. | Pyridoxal analogues and methods of treatment |
US6339085B1 (en) * | 1999-03-08 | 2002-01-15 | The University Of Manitoba | Therapeutics for cardiovascular and related diseases |
US6489345B1 (en) * | 1999-07-13 | 2002-12-03 | Medicure, Inc. | Treatment of diabetes and related pathologies |
US7148233B2 (en) * | 1999-08-24 | 2006-12-12 | Merrill Lynch Capital Canada Inc. | Treatment of cardiovascular and related pathologies |
US7144892B2 (en) * | 1999-08-24 | 2006-12-05 | Merrill Lynch Capital Canada Inc. | Treatment of cardiovascular and related pathologies |
US7132430B2 (en) * | 1999-08-24 | 2006-11-07 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US6677356B1 (en) * | 1999-08-24 | 2004-01-13 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US7125889B2 (en) * | 1999-08-24 | 2006-10-24 | Medicure International Inc. | Treating of cardiovascular and related pathologies |
US7115626B2 (en) * | 1999-08-24 | 2006-10-03 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US7115625B2 (en) * | 1999-08-24 | 2006-10-03 | Medicure International Inc. | Treatment of cardiovascular and related pathologies |
US6667315B2 (en) * | 2000-02-29 | 2003-12-23 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US7105673B2 (en) * | 2000-02-29 | 2006-09-12 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US6867215B2 (en) * | 2000-02-29 | 2005-03-15 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US6780997B2 (en) * | 2000-02-29 | 2004-08-24 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US6605612B2 (en) * | 2000-02-29 | 2003-08-12 | Medicure International Inc. | Cardioprotective phosohonates and malonates |
US6861439B2 (en) * | 2000-03-28 | 2005-03-01 | Medicure International, Inc. | Treatment of cerebrovascular disease |
US6586414B2 (en) * | 2000-03-28 | 2003-07-01 | Medicure International Inc. | Treatment of cerebrovascular disease |
US6897228B2 (en) * | 2000-07-07 | 2005-05-24 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US6417204B1 (en) * | 2000-07-07 | 2002-07-09 | Medicure International Inc. | Pyridoxine AMD pyridoxal analogues: cardiovascular therapeutics |
US6548519B1 (en) * | 2001-07-06 | 2003-04-15 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: novel uses |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040220090A1 (en) * | 1995-09-12 | 2004-11-04 | Kansas University Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US20030008847A1 (en) * | 1999-07-13 | 2003-01-09 | Medicure, Inc. | Treatment of diabetes and related pathologies |
US20040171588A1 (en) * | 2000-02-29 | 2004-09-02 | Wasimul Haque | Cardioprotective phosphonates and malonates |
US7442689B2 (en) | 2000-02-29 | 2008-10-28 | Medicure International Inc. | Cardioprotective phosphonates and malonates |
US7425570B2 (en) | 2000-07-07 | 2008-09-16 | Medicure International Inc. | Pyridoxine and pyridoxal analogues: new uses |
US20070032456A1 (en) * | 2003-03-27 | 2007-02-08 | Friesen Albert D | Modulation of cell death |
US7812037B2 (en) | 2004-10-28 | 2010-10-12 | Medicure International, Inc. | Dual antiplatelet/anticoagulant pyridoxine analogs |
US20070243249A1 (en) * | 2004-11-26 | 2007-10-18 | Friesen Albert D | Novel formulation of pyridoxal-5'-phosphate and method of preparation |
US20080213364A1 (en) * | 2004-11-26 | 2008-09-04 | Medicure International, Inc. | Formulations of Pyridoxal-5'-Phosphate and Methods of Preparation |
US20060148763A1 (en) * | 2005-01-05 | 2006-07-06 | Friesen Albert D | Compounds and methods for regulating triglyceride levels |
US7375112B2 (en) | 2005-01-05 | 2008-05-20 | Medicure International Inc. | Compounds and methods for regulating triglyceride levels |
US20090018106A1 (en) * | 2005-03-30 | 2009-01-15 | Medicure International Inc. | Intravenous formulations of pyridoxal 5'- phosphate and method of preparation |
Also Published As
Publication number | Publication date |
---|---|
AU5840200A (en) | 2001-01-30 |
WO2001003682B1 (en) | 2002-01-24 |
CA2376029A1 (en) | 2001-01-18 |
US20030008847A1 (en) | 2003-01-09 |
US6489345B1 (en) | 2002-12-03 |
WO2001003682A2 (en) | 2001-01-18 |
EP1196171A2 (en) | 2002-04-17 |
WO2001003682A3 (en) | 2001-12-27 |
US20090018052A1 (en) | 2009-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090018052A1 (en) | Treatment of Diabetes and Related Pathologies | |
US7144892B2 (en) | Treatment of cardiovascular and related pathologies | |
US20080139511A1 (en) | Combination Therapies Employing Ace Inhibitors and Uses Thereof for the Treatment of Diabetic Disorders | |
EP2786750B2 (en) | Agent for reducing adverse side effects of kinase inhibitor | |
EP1405638B1 (en) | Pharmaceutical composition comprising quinuclidin-3'-yl 1-phenyl-1,2,3,4,-tetrahydroisoquinoline-2-carboxylate for treatment of interstitial cystitis and/or abacterial prostatitis | |
WO2005079792A1 (en) | Preventive or therapeutic agents for severe diabetic retinopathy | |
KR20030085558A (en) | Biguanide derivatives | |
EP1493443A1 (en) | Use of pyridoxal phosphate for the treatment of diabetes and related complications | |
EP1897547A1 (en) | Use of pyridoxal phosphate derivatives for the treatment of diabetes and related complications | |
EP1832291A2 (en) | use of pyridoxal phosphate for the treatment of diabetes and related complications | |
AU2004275852A1 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
EP1256342B1 (en) | Hypoglycemics comprising organic zinc (ii) complexes | |
MX2014014316A (en) | A method of weight reduction. | |
KR20180051659A (en) | Composition for treating diabetes | |
US9446025B2 (en) | Treatment or prevention of hypotension and shock | |
EP0903144A1 (en) | Remedy for retinal neuropathy | |
US20240033263A1 (en) | Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications | |
TWI662967B (en) | Hypergastric agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MERRILL LYNCH CAPITAL CANADA INC., CANADA Free format text: SECURITY AGREEMENT;ASSIGNOR:MEDICURE INC.;REEL/FRAME:018109/0062 Effective date: 20060811 |
|
AS | Assignment |
Owner name: BIRMINGHAM ASSOCIATES LTD., NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:MEDICURE INC.;REEL/FRAME:019864/0092 Effective date: 20070917 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: MEDICURE INC., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:GE CANADA ASSET FINANCE HOLDING COMPANY, SUCCESSOR AS AGENT TO MERRILL LYNCH CAPITAL CANADA INC.;REEL/FRAME:021924/0657 Effective date: 20081112 |
|
AS | Assignment |
Owner name: MEDICURE INC., CANADA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:BIRMINGHAM ASSOCIATES LTD.;REEL/FRAME:026653/0037 Effective date: 20110718 |